Endometrial carcinoma · line 2 · Dostarlimab monotherapy (GARNET) — 2L+ dMMR endometrial
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-DOSTARLIMAB-MONO-ENDOM |
| ID | IND-ENDOMETRIAL-2L-DOSTARLIMAB-DMMR |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-ENDOMETRIAL |
| Sources | SRC-ESMO-ENDOMETRIAL-2022 SRC-NCCN-UTERINE-2025 |
Notes
STUB — pending Co-Lead sign-off. Aggressive-track 2L for dMMR/MSI-H recurrent endometrial without prior ICI. UA: dostarlimab NSZU-reimbursed for endometrial (1L RUBY indication; 2L use under same onco package per current NSZU protocol — verify). Pembrolizumab labeled alternative if dostarlimab unavailable.
Used By
Algorithms
ALGO-ENDOMETRIAL-2L- ALGO-ENDOMETRIAL-2L